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Risk assessments into the potential for microbicides to select for reduced bacterial susceptibility 29 
have been based largely on data generated through the exposure of bacteria to microbicides in 30 
aqueous solution. Since microbicides are normally formulated with multiple excipients, we have 31 
investigated the effect of formulation on antimicrobial activity and the induction of bacterial 32 
insusceptibility. The susceptibilities of 9 species of bacteria (7 genera) were determined before 33 
and after repeated exposure (14 passages) using a previously validated gradient plating system, 34 
to the microbicides benzalkonium chloride, benzisothiozolinone, chlorhexidine, didecyldimethyl 35 
ammonium chloride, DMDM-hydantoin, polyhexamethylene biguanide, thymol and triclosan in 36 
aqueous solution (non-formulated) and in formulation with excipients often deployed in 37 
consumer products. Susceptibilities were also assessed following an additional 14 passages 38 
without microbicide to determine the stability of any susceptibility changes. Minimum 39 
inhibitory concentrations (MIC) and minimum bactericidal concentrations (MBC) were on 40 
average 11-fold lower for formulated vs. non-formulated microbicides. After antimicrobial 41 
exposure, of 72 combinations of microbicide and bacterium, there were 19 ≥4-fold (mean 8-42 
fold) increases in MIC for non-formulated and 8 ≥4-fold (mean 2-fold) increases in MIC for 43 
formulated microbicides. Furthermore, there were 20 ≥4-fold increases in MBC (mean 8-fold) 44 
for non-formulated and 10 ≥4-fold (mean 2-fold) increases in MBC for formulated 45 
microbicides. Susceptibility decreases fully or partially reverted back to pre-exposure values for 46 
49% of MICs and 72% of MBCs after further passage. In summary, formulated microbicides 47 
exhibited greater antibacterial potency than unformulated actives and susceptibility decreases 48 
following repeated exposure were lower in frequency and extent.  49 
 50 
INTRODUCTION 51 
Microbicides are broad-spectrum chemical agents that inactivate microorganisms (1-3). They 52 
are widely deployed throughout healthcare (4-6), domestic (7, 8) and industrial environments (9-53 
11) where their application includes antisepsis (12), hard surface disinfection (13) and 54 
pharmaceutical product preservation (14). They may also be incorporated into medical device 55 
coatings, for instance in sutures (15), wound dressings (16) and urinary catheters (17) to inhibit 56 
bacterial adhesion and subsequent biofilm formation. 57 
It has been hypothesized that the use of microbicides could select for bacterial adaptation, 58 
resulting in reduced efficacy of the primary agent as well as potentially decreasing bacterial 59 
susceptibility to chemically-unrelated agents such as other microbicides and antibiotics (18). 60 
Whilst there have been reports documenting the laboratory selection of bacteria with decreased 61 
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microbicide sensitivity following repeated exposure to microbicides in highly selective 62 
conditions, it remains unclear whether this commonly occurs in the environment (19-24).  63 
The majority of studies reporting reductions in microbicide susceptibility have used the active 64 
compound in aqueous solution with or without the addition of co-solvents such as DMSO (25) 65 
or ethanol (26, 27). In real use however, microbicides are deployed in formulated products with 66 
multiple excipients that may enhance potency. The potential effect of the formulation of 67 
microbicides on reducing the development of bacterial insusceptibility has received little 68 
research attention. Furthermore, despite the research effort that has been directed towards the 69 
possible risk of induced microbicide insusceptibility, the stability of such susceptibility changes 70 
has been investigated infrequently (24). 71 
 72 
With the ultimate aim of developing realism-based approaches to risk assessment, the current 73 
investigation evaluates the frequency, magnitude and reversibility of susceptibility changes that 74 
may be induced by the repeated exposure of a range of bacteria to microbicides in aqueous 75 
solution or in formulation. The microbicides selected reflect those frequently used in consumer 76 
products such as laundry detergents, hard surface disinfectants and personal care products. 77 
Planktonic susceptibilities (MIC, MBC) and minimum biofilm eradication concentrations 78 
(MBEC) were determined before and after repeated exposure to sub-lethal concentrations of the 79 
microbicides benzalkonium chloride (BAC), benzisothiozolinone (BIT), chlorhexidine (CHX), 80 
didecyldimethyl ammonium chloride (DDAC), glydant (DMDM hydantoin), 81 
polyhexamethylene biguanide (PHMB), thymol, and triclosan in aqueous solution and in 82 
formulation with commonly used sequestrants and surfactants. Bacteria were also passaged 83 
further in the absence of any antimicrobial to determine the stability of any observed change in 84 
susceptibility. 85 
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METHODS 86 
Bacteria. Pseudomonas aeruginosa ATCC 9027, Staphylococcus aureus ATCC 6538, 87 
and Escherichia coli ATCC 25922 were obtained from Oxoid (Basingstoke, UK). Acinetobacter 88 
baumanii (Accession number: JX966428.1), Pseudomonas putida (Accession number: 89 
JQ968690.1), Moraxella osloensis (Accession number: AB643597.1), Escherichia coli 90 
(Accession number: CP003034.1) and Cronobacter sakazakii (Accession number: HQ880381.1) 91 
were isolated from a domestic kitchen drain biofilm. Enterococcus faecalis (Accession number 92 
KJ818115.1) was provided by Angela Oates, The University of Manchester. 93 
Chemical Reagents and Growth Media. Bacteriological growth media was purchased 94 
from Oxoid (Basingstoke, UK). All other chemical reagents were purchased from Sigma-95 
Aldrich (Dorset, UK) unless otherwise stated. Bacterial growth media was sterilized at 121°C 96 
and 15 psi for 15 min prior to use. Pseudomonas aeruginosa, Staphylococcus aureus, 97 
Escherichia coli and Enterococcus faecalis were cultured on Tryptone Soya Agar and Broth. 98 
Acinetobacter baumanii, Pseudomonas putida, Moraxella osloensis and Cronobacter sakazakii 99 
were grown on Wilkins Chalgren agar and broth containing 2% sucrose. All bacteria were 100 
incubated aerobically at 37˚C for 18h unless stated otherwise. 101 
Antimicrobial actives: benzalkonium chloride, chlorhexidine, thymol and triclosan were 102 
purchased from Sigma-Aldrich (Dorset, UK). Didecyldimethyl ammonium chloride (50% v/v) 103 
was purchased from Merck Millipore (Durham, UK). Vantocil (a 20% v/v aqueous solution of 104 
PHMB) was obtained from Arch Chemicals Inc. (Manchester, UK). Glydant (DMDM 105 
hydantoin) was obtained from Lonza (Bishop’s Stortford, UK). All microbicides were tested in 106 
aqueous solution as previously described (27) and in formulation, at concentrations reflective of 107 
their normal deployment in consumer products. BAC, CHX, DDAC, DMDM hydantoin, PHMB 108 
and thymol were prepared at 1% (v/v) in a general purpose cleaner. Triclosan was formulated 109 
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into a laundry detergent at 0.0066% (w/v). Benzisothiozolinone was formulated into a laundry 110 
detergent at 0.02% (v/v). 111 
Exposure of Bacteria to Sub-lethal Concentrations of Microbicides as active and 112 
formulation. A previously validated system (20, 25) was used to generate reproducible c. 100-113 
fold antimicrobial concentration gradients on Tryptone Soya Agar plates using a spiral plater 114 
(Whitley Automated Spiral Plater, Don Whitley Scientific, Shipley, UK). Initial MIC 115 
antimicrobial stock solutions (50μl) were deposited on the agar surface. Plates were dried for 1h 116 
at room temperature prior to radial deposition of bacterial pure cultures and then incubated (4d; 117 
37˚C) in a static aerobic incubator. After incubation, growth observed at the highest microbicide 118 
concentration was aseptically removed and streaked onto a fresh plate containing the same 119 
antimicrobial concentration gradient. Where growth was observed across the whole 120 
antimicrobial gradient, a new plate produced with a five times higher microbicide concentration 121 
was used25. This process was repeated until 14 passages had occurred (P14). Bacteria that 122 
exhibited ≥4-fold changes in MIC, MBC or MBEC were then passaged a further 14 times in the 123 
absence of any antimicrobial (X14) to ascertain the stability of adaptation. Bacteria at P0, P14 124 
and X14 were archived for subsequent MIC and MBC testing. Susceptibility testing (MIC, 125 
MBC, MBEC) was performed in two separate experiments each with three technical replicates. 126 
Determination of bacterial Minimum Inhibitory Concentrations (MIC) and 127 
Minimum Bactericidal Concentrations (MBC). MIC values were determined using the 128 
microdilution method as described previously (28). Briefly, overnight bacterial cultures were 129 
adjusted to an OD600 of 0.8 and diluted 1 in 100 in Tryptone Soya Both or Wilkins Chalgren 130 
Broth with 2% sucrose in a 96-well microtiter plate containing doubling dilutions of the relevant 131 
microbicide. Plates were incubated at 37ºC (24h) with agitation (100rpm). The MIC was defined 132 
as the lowest concentration for which bacterial growth did not occur. Growth was viewed as 133 
turbidity (600nm) in comparison to an uninoculated well (negative control) and was detected 134 
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using a microtiter plate reader (Anthos HTII; Anthos-Labtec Instruments. Salzburg. Austria). 135 
MBCs were determined as stated previously (25), in brief aliquots (10µl) from wells exhibiting 136 
no turbidity were transferred to sterile Tryptone Soya Agar or Wilkins Chalgren Agar prior to 137 
4d incubation at 37ºC to determine the minimum bactericidal concentration (MBC) (25). The 138 
MBC was defined as the lowest concentration of microbicide at which no growth occurred after 139 
4d of incubation.  140 
Determination of Minimum Biofilm Eradication Concentrations. Single species 141 
biofilms were grown on the pegs of a Calgary Biofilm Device (CBD) (29). To produce inocula 142 
for biofilm susceptibility testing, single colonies of test bacteria were inoculated into 10ml of 143 
sterile Tryptone Soya Broth or Wilkins Chalgren Broth with 2% sucrose and incubated at 37˚C 144 
in a shaking aerobic incubator (100rpm) for 18h. Cultures were diluted to an OD600 of 0.8, then 145 
further diluted 1:100 using fresh growth medium. 100μl of bacterial inoculum was added to 146 
each well of the CBD base, plates were then incubated at 37˚C and 30 rpm for 48h to allow 147 
biofilm formation on the pegs. Doubling dilutions for microbicides (150μl) were prepared in 148 
sterile broth across a 96 well microtiter plate. Biofilms were exposed to antimicrobials and 149 
incubated for 24h at 37˚C and 100rpm. After incubation the lid was transferred to a 96-well 150 
plate containing 200μl of sterile broth and was incubated for 24h at 37˚C and 100rpm. Minimum 151 
biofilm eradication concentrations (MBECs) were determined as the lowest concentration for 152 
which bacterial growth did not occur after 18h of incubation. Growth was viewed as turbidity in 153 
comparison to an uninoculated well (negative control) and was detected using a microtiter plate 154 
reader (BioTek, Bedfordshire, UK).  155 
 156 
RESULTS 157 
Two main variables describe data associated with the selection of decreased susceptibility by 158 
exposure to microbicides in the current study; i) the frequency of susceptibility decreases greater 159 
  
7
than two-fold (25) for multiple test bacteria and microbicides and ii) the extent of susceptibility 160 
changes for each combination of bacterium and microbicide.  161 
 162 
Repeated exposure to the microbicide-containing formulations resulted in a lower frequency of 163 
susceptibility reductions than did exposure to the same microbicide in aqueous solutions and, 164 
where decreases in susceptibility did occur; these were generally smaller for formulated 165 
microbicides. All individual values for bacterial susceptibility before, during and after 166 
microbicide exposure have been given in Tables 1-8. However, due to the large number of 167 
combinations of bacterium and antimicrobial that were tested, the extent of susceptibility has 168 
also been expressed as mean values in the following section. 169 
 170 
After repeated exposure to unformulated microbicides there were 19 ≥4-fold increases in MIC 171 
(1 of which fully reverted back to pre-exposure values after subsequent passage in the absence 172 
of microbicide, 13 of which partially reverted and 5 which did not revert; average increase in 173 
MIC (P0 to P14) was 11-fold across the test panel of bacteria and microbicides). There were 20 174 
increases in MBC (2 fully, 11 partially and 7 non-revertible; average 8-fold increase) and 17 175 
increases in MBEC (7 fully, 6 partially and 4 non- revertible; average 4-fold increase) after 176 
microbicide exposure (Tables 1-8). After exposure to microbicide containing formulations there 177 
were 8 ≥4-fold increases in MIC (2 fully and 6 non-revertible; average 2-fold increase), 10 178 
increases in MBC (3 fully, 5 partially and 2 non-revertible; average 2-fold increase) and 16 179 
increases in MBEC (5 fully, 8 partially and 3 non-revertible; average 3-fold increase) (Tables 1-180 
8). In terms of antimicrobial potency, when comparing the formulated to non-formulated 181 
microbicides across the test panel of bacteria we saw an approximately 11-fold lower MIC/ 182 
MBC and 3-fold lower MBEC for the unexposed (P0) bacterial isolates. For the P14 isolates we 183 
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observed an approximately 35-fold lower MIC, 36-fold lower MBC and 4-fold lower MBEC 184 
(Tables 1-8).  185 
Benzalkonium Chloride. All test bacteria, with the exception of M. osloensis, C. 186 
sakazakii and the E. coli drain isolate exhibited a ≥4 fold increase in MIC after exposure to BAC 187 
(Table 1). Increases in MBC, whilst generally smaller than those in MIC, were also observed at 188 
≥4 fold for S. aureus, E. coli and P. aeruginosa. Furthermore ≥4 fold increases in MBEC 189 
occurred for S. aureus and E. faecalis after BAC exposure. After growth in the absence of BAC, 190 
subsequent full or partial reversion in MIC, MBC or MBEC occurred for all test bacteria with 191 
the exception of E. coli and P. aeruginosa (MIC and MBC). In contrast, after exposure to the 192 
BAC formulation only S. aureus, E. coli, P. aeruginosa and A. baumanii showed a ≥4 fold 193 
increase in MIC with S. aureus and E. coli also demonstrating a ≥4 fold increase in MBC. S. 194 
aureus, E. faecalis and P. aeruginosa also exhibited a ≥4 fold increase in MBEC after exposure 195 
to BAC formulation. After recovery in the absence of BAC formulation only S. aureus 196 
demonstrated any reversion in susceptibility (MBEC).  197 
Benzisothiozolinone (BIT). No bacterium displayed a substantial change in 198 
susceptibility (≥4 fold MIC, MBC or MBEC) to BIT or to BIT formulation after long-term 199 
exposure to the respective agent (Table 2). 200 
Chlorhexidine. After repeated exposure to chlorhexidine both S. aureus and E. coli 201 
showed ≥4 fold increases in MIC and MBC which partially reverted in the absence of the 202 
microbicide (Table 3). P. aeruginosa demonstrated a ≥4 fold increase in MIC which did not 203 
revert after regrowth in a chlorhexidine free environment. E. faecalis and M. osloensis exhibited 204 
≥4 fold increases in MBEC, which partially and fully reverted in the absence of chlorhexidine 205 
respectively. In contrast, after exposure to chlorhexidine formulation no bacterium exhibited a 206 
≥4 fold decrease in susceptibility at MIC, MBC or MBEC level. 207 
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Didecyldimethyl Ammonium Chloride. After repeated DDAC exposure P. aeruginosa, 208 
A. baumanii and the E .coli drain isolate exhibited a ≥4 fold increase in MBC, of which P. 209 
aeruginosa fully reverted whilst A. baumanii and E. coli partially reverted following repeated 210 
growth the absence of DDAC. S. aureus. E. coli, E. faecalis and the E. coli drain isolate all 211 
exhibited a ≥4 fold increase in MBEC, out of which E. faecalis and the E. coli drain isolate 212 
partially reverted, E. coli fully reverted and S. aureus did not revert back to pre-exposure values 213 
following growth in the absence of the microbicide (Table 4). After exposure to the DDAC-214 
containing formulation, P. aeruginosa and the E. coli drain isolate exhibited a ≥4 fold increase 215 
in MBC, out of which E. coli partially reverted and P. aeruginosa fully reverted after passage in 216 
an antimicrobial free environment. In agreement with the changes in MBEC observed after 217 
exposure to DDAC active, S. aureus, E. coli, E. faecalis and the E. coli drain isolate also 218 
showed a ≥4 fold increase in MBEC after exposure to DDAC formulation. MBEC values 219 
partially reverted for both E. coli isolates and for E. faecalis but did not revert for S. aureus after 220 
recovery in the absence of DDAC.  221 
Glydant (DMDM Hydantoin). The E. coli drain isolate exhibited a ≥4 fold increase in 222 
MBC after repeated exposure to DMDM hydantoin; this susceptibility decrease fully reverted in 223 
the absence of the microbicide (Table 5). Comparatively after exposure to DMDM hydantoin 224 
formulation both E. coli isolates as well as C. sakazakii showed a ≥4 fold increase in MBEC, all 225 
of which fully reverted in an antimicrobial free environment. 226 
Polyhexamethylene Biguanide. S. aureus, E. faecalis M. osloensis and A. baumanii 227 
exhibited a ≥4 fold increase in MIC after PHMB exposure out of which M. osloensis and A. 228 
baumanii fully reverted and S. aureus and E. faecalis partially reverted after growth in the 229 
absence of PHMB (Table 6). S. aureus, E. coli, P. aeruginosa, E. faecalis, and the E. coli drain 230 
isolate demonstrated a ≥4 fold increase in MBC out of which S. aureus, E. faecalis and the E. 231 
coli drain isolate showed partial reversion and E. coli and P. aeruginosa showed no reversion to 232 
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pre-exposure values in the absence of PHMB. After PHMB exposure, S. aureus, E. faecalis, A. 233 
baumanii, C. sakazakii, and the E. coli drain isolate also displayed a ≥4 fold increase in MBEC, 234 
which fully reverted for S. aureus, A. baumanii and E. coli drain isolate, and partially reverted 235 
for E. faecalis and C. sakazakii after re-growth in the absence of PHMB. After exposure to 236 
PHMB formulation S. aureus, E. faecalis and P. aeruginosa showed substantial changes in their 237 
PHMB susceptibility displaying ≥4 fold increases in MBC all of which fully or partially 238 
reverted in the absence of the antimicrobial formulation. S. aureus and E. faecalis also exhibited 239 
a ≥4 fold increase in MBEC after exposure to PHMB formulation, all of which partially reverted 240 
back to pre-exposure values after regrowth in the absence of the formulation. 241 
Thymol. After long-term thymol exposure none of the bacterial isolates showed a ≥4 242 
fold decrease in thymol susceptibility at MIC, MBC or MBEC level (Table 7). After exposure to 243 
the thymol-containing formulation, E. coli and A. baumanii both underwent ≥4 fold increases in 244 
MBC whilst P. putida demonstrated a ≥4 fold increase in MIC and MBC, all of which partially 245 
reverted in the absence of thymol formulation. Furthermore, both E. coli isolates showed a ≥4 246 
fold increase in MBEC, which partially reverted after growth in the absence of thymol 247 
formulation.  248 
Triclosan. All bacterial isolates, with the exception of E. faecalis, A. baumanii and P. 249 
aeruginosa, which is non-susceptible to triclosan, demonstrated an increase in MIC after 250 
repeated triclosan exposure, none of which fully reverted back to pre-exposure levels after 251 
regrowth in the absence of triclosan (Table 8). All isolates apart from P. aeruginosa, A. 252 
baumanii and P. putida showed a ≥4 fold increase in MBC out of which C. sakazakii and the E. 253 
coli drain isolate showed partial reversion, whilst the others showed no reversion after passage 254 
in the absence of triclosan. Both E. coli isolates in addition to C. sakazakii, E. faecalis and A. 255 
baumanii showed ≥4 fold increase in MBEC after repeated triclosan exposure out of which C. 256 
sakazakii and E. faecalis did not revert and both E. coli isolates completely reverted in the 257 
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absence of the microbicide. In comparison after exposure to triclosan formulation only the E. 258 
coli isolates and P. aeruginosa showed ≥4 fold increase in MIC, which fully reverted for P. 259 
aeruginosa but did not revert for either E. coli strain in the absence of triclosan formulation. 260 
MBECs increased ≥4 fold for S. aureus and E. faecalis but fully reverted for both bacteria after 261 
regrowth in the absence of triclosan formulation.  262 
 263 
DISCUSSION 264 
The majority of investigations into the potential of microbicides to select for changes in 265 
bacterial susceptibility have been conducted by exposing pure cultures of bacteria to 266 
microbicides as pure actives in aqueous solution or in simple formulations (aqueous solutions 267 
containing the active and in some studies, cosolvents such as DMSO (25) or ethanol (27)). It has 268 
been hypothesized that formulated products may interact with bacteria in a manner that is 269 
distinct from aqueous solutions (28, 30) potentially reducing the frequency and extent of 270 
susceptibility reductions. Whilst numerous studies have evaluated the antimicrobial potency of 271 
formulated microbicides (3, 31, 32), to our knowledge there are no studies in the literature that 272 
have compared the effects of repeated bacterial exposure to microbicides in aqueous solution 273 
and in complex formulation, for a range of bacteria and microbicides. In the current 274 
investigation therefore, we have evaluated the effect of the formulation of microbicides on 275 
antimicrobial potency and on the mitigation of bacterial insusceptibility for a selection of 276 
bacterial isolates and microbicides encompassing biguanides, quaternary ammonium 277 
compounds, phenolics, isothiazolinones, formaldehyde releasers and essential oils. Microbicides 278 
were tested as aqueous solutions of the active compounds and in complex formulations with 279 
sequestrants and ionic/non-ionic surfactants to mimic their real world use as hard-surface 280 
disinfectants (for BAC, chlorhexidine, DDAC, DMDM hydantoin, PHMB and thymol), and 281 
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laundry detergents (for BIT and triclosan). The reversibility of any induced susceptibility 282 
changes was also investigated to ascertain the stability of adaptation.  283 
 284 
Reductions in bacterial susceptibility to an antimicrobial agent can be influenced by several 285 
factors related to the antimicrobial or the microorganism. Bacterial susceptibility may be 286 
affected by the structural integrity of the bacterial cell envelope and its ability to function as an 287 
effective permeability barrier (33-35). Innate bacterial non-susceptibility towards an 288 
antimicrobial agent may occur due to effective barrier components of the bacterial cell, such as 289 
an outer membrane in Gram-negative bacteria (36) or the spore coat in bacterial endospores 290 
(37). Changes in cell envelope permeability may therefore affect bacterial susceptibility which 291 
can include alterations in lipopolysaccharide expression and structure33, reduction in the 292 
number of outer membrane porins (23) and alterations in membrane fatty acid composition (38). 293 
The expression of efflux pumps has also been linked to decreases in microbicide susceptibility 294 
in bacteria, particularly towards membrane-active compounds such as biguanides (39) (CHX 295 
and PHMB) and quaternary ammonium compounds40 (BAC and DDAC in the current 296 
investigation). The increased expression of efflux pumps may therefore also provide a plausible 297 
explanation for some of the susceptibility changes observed in many of our bacterial isolates. 298 
Reversible susceptibility changes to microbicides may result from temporary phenotypic 299 
adaptations in bacteria, such as the induction of stress responses that revert once the bacteria 300 
recover in an antimicrobial-free environment (41, 42). Equally, the development of microbicide 301 
insusceptibility may be attributable to the selection of insusceptible mutants, for instance 302 
mutations in FabI are reportedly render some bacteria insusceptible to triclosan (43, 44). 303 
However, the inherent stability of a particular mutation largely depends upon the overall fitness 304 
cost that it exerts on the host microorganism versus the competitive advantage that it provides in 305 
a particular environment (45). Hence, any mutation that renders a bacterium less susceptible 306 
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towards an antimicrobial agent may eventually be lost once the selective pressure is removed if 307 
the mutation results in a biologically significant reduction in the fitness of the microorganism 308 
(46).  309 
 310 
Whilst previous studies have reported the induction of microbicide insusceptibility in bacteria, it 311 
should be noted that adapted bacterial isolates often remain susceptible to the microbicide at 312 
concentrations used in consumer products, and that true microbicide resistance is likely to be 313 
uncommon (25). In the current investigation, the only test bacterium that was refractory to a 314 
microbicide was P. aeruginosa to triclosan. This was apparent before microbicide exposure and 315 
has previously been attributed to the expression of efflux pumps 47. Interestingly this bacterium 316 
was comparatively susceptible to the triclosan formulation, illustrating marked differences in 317 
potency for the microbicide in aqueous solution compared to the formulated product. 318 
 319 
Out of all the microbicides in unformulated form, BAC and triclosan induced the highest 320 
frequency of ≥4-fold increases in MIC with 6/9 bacterial isolates showing a reduction in 321 
susceptibility to both antimicrobials at this level. This was followed by PHMB (4 isolates) and 322 
CHX (3 isolates). Triclosan exposure resulted in the highest frequency of ≥4-fold increases in 323 
MBC (6 isolates) followed by PHMB (5 isolates), DDAC and BAC (3 isolates), then CHX (2 324 
isolates) and DMDM hydantoin (1 isolate). In terms of the susceptibility of bacteria when grown 325 
as biofilms, PHMB adaptation resulted in the highest number of isolates showing ≥4-fold 326 
increases in MBEC (5 isolates) followed by triclosan and DDAC (4 isolates each) then BAC and 327 
CHX (2 isolates).  328 
 329 
With respect to the formulated microbicides, BAC induced the highest number of ≥4-fold 330 
increases in MIC (4 isolates) followed by triclosan (3 isolates) and thymol (1 isolate). DMDM 331 
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hydantoin, thymol and PHMB containing formulations induced the largest number of ≥4-fold 332 
increases in MBC (3 isolates each) followed by BAC and DDAC (2 isolates each). Exposure to 333 
the DDAC containing formulations resulted in the highest numbers of bacterial isolates 334 
exhibiting a ≥4-fold increase in MBEC (4 isolates), followed by BAC and DMDM hydantoin (3 335 
isolates) then PHMB, thymol and triclosan formulations (2 isolates). 336 
 337 
Whilst the current investigation demonstrates that induced reductions in susceptibility towards 338 
both microbicides and microbicide-containing formulations may occur, a substantially higher 339 
number of bacterial isolates underwent ≥4-fold increases in MIC, MBC or MBEC when exposed 340 
to microbicides in aqueous solution, in comparison to those in formulation. The only exception 341 
to this was thymol, for which changes in susceptibility were more frequent in bacteria exposed 342 
to the compound in formulation. Thymol is poorly soluble in water and formulation may 343 
therefore have substantially improved solubility, increasing bacterial exposure and thus 344 
selectivity. Furthermore, since incorporating microbicides into formulations frequently 345 
enhanced antimicrobial potency, the formulated microbicides often maintained higher 346 
antimicrobial activity in comparison to microbicides in aqueous solution, even after repeated 347 
exposure. The incorporation of non-ionic surfactants and sequestrants into microbicide-348 
containing formulations therefore appears to increase antimicrobial potency as well as 349 
mitigating the development of antimicrobial insusceptibility both in terms of frequency and 350 
magnitude of susceptibility change. Since excipients can interact with different cellular targets 351 
to the accompanying microbicide, formulations may have a cumulative antimicrobial effect 352 
which would require multiple further physiological adaptations to render the microorganism 353 
insusceptible.  354 
 355 
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Alcohol ethoxylates are a major class of non-ionic surfactants which are often used in household 356 
detergents, cleaners and personal care products and have previously shown bacteriostatic effects 357 
due to their direct impact on the bacterial cell membrane leading to the leakage of cytoplasmic 358 
components, indicating an increase in membrane permeability (48). An increase in membrane 359 
permeability would allow microbicides to more readily transverse the cytoplasmic membrane 360 
increasing their access to intracellular target sites. Therefore combining microbicides and 361 
alcohol ethoxylates in formulation may enhance overall antimicrobial potency, when compared 362 
to the pure active. Sodium tripolyphosphate, a chelating agent commonly used in domestic 363 
detergents, has previously shown antibacterial activity against several bacteria often found as 364 
food contaminants (49). Since sodium tripolyphosphate is a chelating agent it is plausible, as 365 
with other chelators such as EDTA, which this antibacterial activity occurs by disruption of the 366 
bacterial cell envelope through the sequestration of stabilising divalent cations. Such cations 367 
normally link bacterial lipopolysaccharides to the outer membrane and interference with this 368 
process can destabilise the outer membrane in Gram negative bacteria, impairing barrier 369 
function (50-52). Furthermore, strong chelating agents may inhibit bacterial growth by 370 
sequestering trace minerals required for bacterial metabolism (51, 53).  371 
 372 
Essential oils such as thymol are often incorporated into antimicrobial formulation due to their 373 
inhibitory effects on bacterial growth. The antimicrobial activity of essential oils reportedly 374 
occurs through interaction with the bacterial cytoplasmic membrane, resulting in increased cell 375 
permeability and the disruption of energy generation (54, 55). Compensatory adaptations may 376 
occur, but whether these would result in outcome-changing effects during deployment depends 377 
on the extent of any susceptibility decreases, the concentration used in the product and the 378 
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antimicrobial potency of the formulation (i.e. the active compound and excipients in 379 
combination). 380 
CONCLUSION 381 
With the ultimate aim of developing realistic approaches to risk assessment, we observed that 382 
repeated exposure of 9 bacteria to 8 microbicides in aqueous solution or within complex 383 
formulations with sequestrants and ionic/non-ionic surfactants, induced reductions in bacterial 384 
susceptibility in a highly selective laboratory exposure system. Susceptibility changes varied in 385 
reversibility, possibly reflecting a range of underlying mechanisms including temporary 386 
phenotypic adaptation, such as the induction of stress responses or the selection of stable 387 
mutations. Importantly, the formulation of microbicides markedly increased overall 388 
antimicrobial potency for the test microbicides against the majority of the bacteria, as well as 389 
reducing the frequency and magnitude of susceptibility changes. Whilst it remains unclear how 390 
observations based on the in vitro exposure of bacteria to microbicides can be extrapolated to 391 
their use in the real world, understanding the potential selectivity of microbicide-containing 392 
formulations is likely to better served by testing formulations as well as actives aqueous 393 
solutions. This highlights the need to conduct risk assessments of induced microbicide 394 
susceptibility changes using conditions that more accurately reflect their deployment. 395 
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Table 1. Bacterial susceptibility towards benzalkonium chloride in planktonic and biofilm growth modes before, during and after repeated exposure to 539 
benzalkonium chloride in aqueous solution or in formulation 540 
MIC, minimum inhibitory concentration; MBC, minimum bactericidal concentration; MBEC, minimum biofilm eradication concentration.  541 
Before antimicrobial exposure (P0); during antimicrobial exposure (P14) and after passage in the absence of antimicrobial (X14) All values are in mg/L. †, 542 
non-drain isolates; *, drain isolates. UF, unformulated (microbicide in aqueous solution); F, formulated (microbicide in formulation). Organisms that 543 
underwent a ≥4-fold increase in MIC, MBC or MBEC (as indicated by bold text) were passaged a further 14 times in the absence of microbicide. na, bacteria 544 
that did not undergo a ≥4-fold change and were not assessed for reversibility. Data represents six replicates. Where data varied between biological replicates, 545 
standard deviations have been given in parentheses. In controls were bacteria were tested against formulations without microbicide, all bacteria were non-546 
susceptible to in-use concentrations. 547 
548 
 
 
 
Bacterium  
MIC MBC MBEC 
UF F UF F UF F 
P0 P14 X14 P0 P14 X14 P0 P14 X14 P0 P14 X14 P0 P14 X14 P0 P14 X14 
S. aureus† 0.1 3.9 2.0 0.5 2.0 2.0 2.0  15.6 7.8 2.0 7.8 7.8 2.6 (1) 31.3 15.6 3.9 125 7.8 
E. coli† 4.6 (1) 31.3 31.3 3.9 31.3 31.3 7.2 (2) 41.7 (16) 62.5 7.8 31.3 62.5 31.3 31.3 62.5 31.3 62.5 62.5 
E. faecalis† 2.0 7.8 3.9 2.0 3.9 3.9 3.3 (1) 7.8 7.8 3.9 7.8 7.8 6.5 (1) 31.3 7.8 6.7 (2) 46.9 (17) 46.9 (17) 
P. aeruginosa† 14.3 (2) 62.5 62.5 15.6 62.5 125 23.4 (9) 125 125 31.3 62.5 250 125 250 500 62.5 250 500 
M. osloensis* 3.9 2.0    na 1.0 1.0 na 7.8 15.6 na 2.0 2.0 na 7.8 na na 7.8 2.0 na 
A. baumanii* 2.0 62.5 31.3 3.9 31.3 31.3 93.8 (34) 250 125 62.5 62.5 125 125 250 125 125 125 93.8 (34) 
P. putida* 15.6 62.5 31.3 15.6 15.6 na 125 125 62.5 62.5 31.3 na 125 na 62.5 125 31.3 na 
C. sakazakii* 62.5 52.1 (16) na 31.3 31.3 na 125 125 na 31.3 31.3 na 31.3 na na 31.3 62.5 na 
E. coli* 18.4 (7) 52.1 (16) na 15.6 31.3 na 62.5 125 na 31.3 31.3 na 62.5 na na 62.5 62.5 na 
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 549 
Table 2. Bacterial susceptibility towards benzisothiozolinone in planktonic and biofilm growth modes before, during and after repeated exposure to 550 
benzisothiozolinone in aqueous solution or in formulation 551 
See footnote in Table 1 552 
553 
 
 
Bacterium  
MIC MBC MBEC 
UF F UF F UF F 
P0 P14 X14 P0 P14 X14 P0 P14 X14 P0 P14 X14 P0 P14 X14 P0 P14 X14 
S. aureus† 7.8 15.6 na 1.0 2.0 na 31.3 62.5 na 15.6 15.6 na 62.5 62.5 na 31.3 62.5 na 
E. coli† 15.6 15.6 na 7.8 7.8 na 31.3 62.5 na 31.3 31.3 na 250 187.5 (68) na 125 125 na 
E. faecalis† 7.8 15.6 na 0.5 1.0 na 7.8 7.8 na 0.5 1.0 na 250 41.7 (16) na 125 125 na 
P. aeruginosa† 125 250 na 15.6 31.3 na 250 500 na 62.5 125 na 500 500 na 125+ 125+ na 
M. osloensis* 1.0 1.0 na 0.5 0.5 na 1.0 1.0 na 0.5 0.5 na 2.0 2.0 na 0.5 1.0 na 
A. baumanii* 31.3 31.3 na 7.8 15.6 na 31.3 62.5 na 31.3 62.5 na 250 250 na 62.5 125 na 
P. putida* 15.6 31.3 na 31.3 31.3 na 62.5 62.5 na 31.3 62.5 na 250 250 na 62.5 125 na 
C. sakazakii* 7.8 7.8 na 7.8 7.8 na 31.3 31.3 na 31.3 31.3 na 250 500 na 62.5 125 na 
E. coli* 15.6 31.3 na 15.6 15.6 na 62.5 62.5 na 15.6 31.3 na 250 187.5 na 125 125 na 
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 555 
Table 3. Bacterial susceptibility towards chlorhexidine in planktonic and biofilm growth modes before, during and after repeated exposure to chlorhexidine 556 
in aqueous solution or in formulation 557 
See footnote in Table 1 558 
 559 
 560 
561 
 
 
 
 
Bacterium  
MIC MBC MBEC 
UF F UF F UF F 
P0 P14 X14 P0 P14 X14 P0 P14 X14 P0 P14 X14 P0 P14 X14 P0 P14 X14 
S. aureus† 1.7 (1) 7.8 3.9 2.0 2.0 na 5.2 (2) 46.9 (17) 31.3 7.8 7.8 na 13 (4) 31.3 31.3 7.8 15.6 na 
E. coli† 2.4 (1) 11.7 (4) 7.9 2.0 3.9 na 9.8 (5) 62.5 31.3 15.6 31.3 na 52.1 (16) 62.5 31.3 62.5 31.3 na 
E. faecalis† 3.9 7.8 15.6 3.9 7.8 na 14.3 (3) 31.3 31.3 7.8 15.6 na 31.3 125 62.5 31.3 62.5 na 
P. aeruginosa† 7.8  31.3 31.3 7.8 15.6 na 68.8 (34) 250 125 125 125 na 250 125 125 250 125 na 
M. osloensis* 3.9 2.0 2.0 1.0 1.0 na 31.3 15.6 3.9 1.0 1.0 na 31.3 125 15.6 15.6 31.3 na 
A. baumanii* 7.8 7.8 na 3.9 7.8 na 125 62.5 na 15.6 31.3 na 125 125 na 125 31.3 na 
P. putida* 7.8 7.8 na 4.6 (2) 3.9 na 93.8 (34) 62.5 na 7.8 7.8 na 62.5 125 na 62.5 62.5 na 
C. sakazakii* 7.8 7.8 na 3.9 3.9 na 62.5 125 na 7.8 15.6 na 62.5 125 na 31.3 10.4 (4) na 
E. coli* 7.8 10.4 (4) 15.6 3.9 3.9 na 46.8 (17) 125 125 7.8 15.6 na 125 125 125 62.5 23.4 (9) na 
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 563 
Table 4. Bacterial susceptibility towards didecyldimethyl ammonium chloride in planktonic and biofilm growth modes before, during and after repeated 564 
exposure to didecyldimethyl ammonium chloride in aqueous solution or in formulation  565 
See footnote in Table 1 566 
 567 
 568 
 569 
 
 
 
Bacterium  
MIC MBC MBEC 
UF F UF F UF F 
P0 P14 X14 P0 P14 X14 P0 P14 X14 P0 P14 X14 P0 P14 X14 P0 P14  
S. aureus† 0.5 1.0 1.0 0.5 0.5 0.5 2.0 3.9 3.9 2.0 0.5 0.5 3.9 31.3 31.3 3.9 62.5 62.5 
E. coli† 7.8 11.7 (4) 7.8 3.9 7.8 3.9 3.9 11.7 (4) 15.6 3.9 7.8 3.9 31.3 125 15.6 7.8 36.5 (13) 15.6 
E. faecalis† 1.0 2.0 2.0 2.0 2.0 2.0 1.0 2.0 2.0 2.0 3.9 3.9 2.0 125 31.3 2.0 104.2 (32) 62.5 
P. aeruginosa† 14.3 (2) 31.3 15.6 15.6 31.3 15.6 31.3 125 31.3 31.3 125 31.3 125 125 250 62.5 125 62.5 
M. osloensis* 1.0 1.0 1.0 1.0 1.0 na 1.4 (0.5) 3.9 2.0 2.0 2 na 2.0 3.9 3.9 2.0 2.0 na 
A. baumanii* 15.6 31.3 15.6 3.9 7.8 na 15.6 62.5 31.3 62.5 62.5 na 62.5 125 31.3 62.5 62.5 na 
P. putida* 47.4 (17) 31.3 na 4.6(1) 3.9 na 62.5 41.7 (17) na 31.3 62.5 na 62.5 62.5 na 62.5 62.5 na 
C. sakazakii* 7.2 (2) 15.6 15.6 7.8 15.6 na 15.6 31.3 31.3 7.8 15.6 na 31.3 62.5 62.5 15.6 31.3 na 
E. coli* 4.6 (2) 15.6 15.6 3.9 7.8 3.9 10.4 (4) 41.7 (17) 31.3 3.9 15.6 7.8 15.6 62.5 31.3 15.6 62.5 23.5 (9) 
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Table 5. Bacterial susceptibility towards Glydant (DMDM-hydantoin) in planktonic and biofilm growth modes before, during and after repeated exposure to 571 
Glydant (DMDM-hydantoin) in aqueous solution or in formulation. 572 
See footnote in Table 1 573 
 574 
575 
 
 
 
Bacterium  
MIC MBC MBEC 
UF F UF F UF F 
P0 P14 X14 P0 P14 X14 P0 P14 X14 P0 P14 X14 P0 P14 X14 P0 P14 X14 
S. aureus† 187.5 187.5 na 187.5 187.5 na 375 482 (183) na 375 375 na 3000 3000 na 1500 3000 na 
E. coli† 375 375 na 375 375 375 1500 1500 na 375 750 375 6000 6000 na 1500 6000 1500 
E. faecalis† 187.5 187.5 na 187.5 187.5 na 1500 1500 na 1500 750 na 3000 3000 na 3000 6000 na 
P. aeruginosa† 187.5 187.5 na 187.5 187.5 na 6000 6000 na 1500 1500 na 6000 6000 na 6000 12000 na 
M. osloensis* 375 375 na 46.9 62.5 na 325 375 na 187.5 187.5 na 750 1500 na 750 1500 na 
A. baumanii* 375 325 na 187.5 187.5 na 750 750 na 375 375 na 6000 6000 na 6000 6000 na 
P. putida* 375 375 na 375 375 na 750 750 na 750 375 na 6000 6000 na 3000 6000 na 
C. sakazakii* 375 375 na 187.5 187.5 375 3000 3000 na 375 750 375 6000 6000 na 1500 6000 1500 
E. coli* 187.5 466 (219) 187.5 187.5 375 187.5 375 1500 375 375 750 375 6000 6000 6000 1500 12000 1500 
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Table 6. Bacterial susceptibility towards PHMB in planktonic and biofilm growth modes before, during and after repeated exposure to PHMB in aqueous 577 
solution or in formulation 578 
See footnote in Table 1 579 
 580 
 581 
 582 
 583 
 584 
 
 
 
Bacterium  
MIC MBC MBEC 
UF F UF F UF F 
P0 P14 X14 P0 P14 X14 P0 P14 X14 P0 P14 X14 P0 P14 X14 P0 P14 X14 
S. aureus† 3.9 23.5 (9) 15.6 3.9 3.9 3.9 3.9 125 15.6  3.9 15.6 7.8 15.6 125 15.6 15.6 125 31.3 
E. coli† 15 (10) 31.3 15.6 7.8 15.6 na 15 (10) 62.5 62.5 15.6 31.3 na 62.5 62.5 62.5 62.5 31.3 na 
E. faecalis† 7.8 31.3 15.6 5.9(1) 15.6 7.8 7.8 125 15.6 7.8 31.3 7.8 14.3 (3) 125 31.3 15.6 125 31.3 
P. aeruginosa† 22.8 (15) 31.3 62.5 15.6 15.6 15.6 22.8 (15) 125 125 31.3 125 31.3 250 250 250 250 62.5 62.5 
M. osloensis* 7.8 31.3 3.9 1.0 1.0 na 62.5 31.3 31.3 7.8 7.8 na 62.5 62.5 31.3 31.3 62.5 na 
A. baumanii* 7.8 31.3 7.8 9.1 (3) 15.6 na 62.5 125 62.5 31.3 62.5 na 62.5 250 62.5 62.5 125 na 
P. putida* 28.9 (8) 31.3 na 15.6 15.6 na 62.5 62.5 na 31.3 62.5 na 125 125 na 125 125 na 
C. sakazakii* 7.8 15.6 15.6 31.2 15.6 na 104 (32) 125 125 15.6 31.3 na 62.5 250 125 62.5 125 na 
E. coli* 7.8 7.8 31.3 7.8 15.6 na 15.6 250 31.3 15.6 31.3 na 62.5 250 31.3 62.5 31.3 na 
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Table 7. Bacterial susceptibility towards thymol in planktonic and biofilm growth modes before, during and after repeated exposure to thymol in aqueous 585 
solution or in formulation 586 
See footnote in Table 1 587 
 588 
 589 
 590 
 591 
 592 
 
 
 
Bacterium  
MIC MBC MBEC 
UF F UF F UF F 
P0 P14 X14 P0 P14 X14 P0 P14 X14 P0 P14 X14 P0 P14 X14 P0 P14 X14 
S. aureus† 187.5 187.5 na 187.5 187.5 na 375 375 na 375 750 na 416 (160) 375 na 375 750 na 
E. coli† 1500 1500 na 187.5 375 375 1500 1500 na 375 1500 750 1500 1500 na 375 3000 1500 
E. faecalis† 375 750 na 187.5 375 na 750 750 na 375 750 na 750 750 na 750 1500 na 
P. aeruginosa† 3000 3000 na 1500 3000 na 6000 3000 na 3000 6000 na 6000 6000 na 6000 12000 na 
M. osloensis* 750 750 na 187.5 375 na 750 750 na 187.5 375 na 3000 1500 na 3000 375 na 
A. baumanii* 750 750 na 375 375 375 1500 3000 na 750 6000 3000 6000 6000 na 6000 6000 6000 
P. putida* 750 750 na 375 3000 375 1500 3000 na 1500 6000 3000 6000 6000 na 6000 6000 12000 
C. sakazakii* 750 750 na 375 375 na 2250 (822) 3000 na 375 750 na 6000 6000 na 3000 750 na 
E. coli* 665 (190) 750 na 187.5 375 na 3000 3000 na 375 750 na 6000 6000 na 750 3000 1500 
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Table 8. Bacterial susceptibility towards triclosan in planktonic and biofilm growth modes before, during and after repeated exposure to triclosan in aqueous 593 
solution or in formulation 594 
See footnote in Table 1. ns, not susceptible (MBC/MIC/MBEC >1000 mg/L) 595 
 596 
 597 
 598 
 599 
 
 
Bacterium  
MIC MBC MBEC 
UF F UF F UF F 
P0 P14 X14 P0 P14 X14 P0 P14 X14 P0 P14 X14 P0 P14 X14 P0 P14 X14 
S. aureus† 0.2 62.5 31.3 0.1 0.1 0.1 3.9 62.5 62.5 0.1 0.1 0.1 65.1 125 125 2.0 7.8 2.0 
E. coli† 2.0 62.5 62.5 0.1 2.0 3.9 2.0 125 125 7.8 7.8 3.9 125 500 125 62.5 15.6 15.6 
E. faecalis† 62.5 62.5 62.5 0.1 0.1 0.1 62.5 125 125 0.1 0.1 0.1 15.6 125 125 2.0 7.8 2.0 
P. aeruginosa† ns ns ns 7.8 62.5 7.8 ns ns ns 62.5 62.5 7.8 ns ns ns 62.5 62.5 7.8 
M. osloensis* 1.0 15.6 7.8 1.0 1.0 na 7.8 31.3 31.3 3.9 3.9 na 125 125 125 3.9 3.9 na 
A. baumanii* 125 125 125 2.0 2.0 na 125 250 125 31.6 15.6 na 125 250 125 62.5 15.6       na 
P. putida* 15.6 62.5 62.5 1.0 2.0 na 62.5 125 125 15.6 15.6 na 125 250 500 62.5 15.6 na 
C. sakazakii* 7.8 500 188 2.0 2.0 na 7.8 1000 250 31.3 31.3 na 1.3 (0.5) 125 125 62.5 31.3 na 
E. coli* 1.0 125 62.5 0.1 2.0 3.9 2.0 250 125 15.6 15.6 15.6 125 500 125 62.5 15.6 15.6 
